{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:13:39Z","timestamp":1784175219261,"version":"3.55.0"},"reference-count":27,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016471","name":"Agios Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100016471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,2,26]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Pyruvate kinase (PK) deficiency is a rare, under-recognised, hereditary condition that leads to chronic haemolytic anaemia and potentially serious secondary complications, such as iron overload, cholecystitis, pulmonary hypertension and extramedullary haematopoiesis. It is an autosomal recessive disease caused by homozygous or compound heterozygous mutations in the\n                      <jats:italic>PKLR<\/jats:italic>\n                      gene. Due to its rarity and clinical heterogeneity, information on the natural history and long-term clinical course of PK deficiency is limited, presenting major challenges to patient management, the development of new therapies and establishing disease-specific treatment recommendations. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry is an initiative to address the gaps in the knowledge of PK deficiency. This manuscript describes the objectives, study design and methodology for the Peak Registry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The Peak Registry is an observational, longitudinal, global registry of adult and paediatric patients with a genetically confirmed diagnosis of PK deficiency. The Peak Steering Committee is composed of 11 clinicians and researchers with experience in the diagnosis and management of PK deficiency from 10 countries, a patient representative and representatives from the sponsor (Agios Pharmaceuticals). The registry objective is to foster an understanding of the longitudinal clinical implications of PK deficiency, including its natural history, treatments and outcomes, and variability in clinical care. The aim is to enrol up to 500 participants from approximately 60 study centres across 20 countries over 7 years, with between 2 and 9 years of follow-up. Data will include demographics, diagnosis history, genotyping, transfusion history, relevant clinical events, medications, emergency room visits and hospitalisations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Registry protocol and informed consent forms are approved by institutional review boards\/independent ethics committees at each study site. The study is being conducted in accordance with the Declaration of Helsinki. Registry data will be published in peer-reviewed journal articles and conference publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03481738\">NCT03481738<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063605","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T11:35:20Z","timestamp":1679571320000},"page":"e063605","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03481738","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04105166","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02053480","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03481738","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04964323","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04995315","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03481738","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rachael F","family":"Grace","sequence":"first","affiliation":[{"name":"Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard J","family":"van Beers","sequence":"additional","affiliation":[{"name":"Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan-Lluis","family":"Vives Corrons","sequence":"additional","affiliation":[{"name":"Institute for Leukaemia Research Josep Carreras ENERCA Coordinator, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Glader","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Glenth\u00f8j","sequence":"additional","affiliation":[{"name":"Danish Red Blood Cell Center, Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Processing, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H M","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Lander","sequence":"additional","affiliation":[{"name":"Thrive with PK Deficiency, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Mark","family":"Layton","sequence":"additional","affiliation":[{"name":"Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Posp\u00ed\u015dilov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Palacky University and University Hospital, Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vip","family":"Viprakasit","sequence":"additional","affiliation":[{"name":"Siriaj Hospital, Mahidol University, Salaya, Nakhon Pathom, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Li","sequence":"additional","affiliation":[{"name":"Agios Pharmaceuticals Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[{"name":"Agios Pharmaceuticals Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audra N","family":"Boscoe","sequence":"additional","affiliation":[{"name":"Agios Pharmaceuticals Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bowden","sequence":"additional","affiliation":[{"name":"Agios Pharmaceuticals Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Pathophysiology of Anemias Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"2025121409572297000_13.3.e063605.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810796"},{"key":"2025121409572297000_13.3.e063605.2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.196295"},{"key":"2025121409572297000_13.3.e063605.3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejh.13424","article-title":"Prevalence of pyruvate kinase deficiency: a systematic literature review","volume":"105","author":"Secrest","year":"2020","journal-title":"Eur J Haematol"},{"key":"2025121409572297000_13.3.e063605.4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ajh.25325","article-title":"Addressing the diagnostic gaps in pyruvate kinase deficiency: consensus recommendations on the diagnosis of pyruvate kinase deficiency","volume":"94","author":"Bianchi","year":"2019","journal-title":"Am J Hematol"},{"key":"2025121409572297000_13.3.e063605.5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.25753","article-title":"Genotype-Phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency","volume":"95","author":"Bianchi","year":"2020","journal-title":"Am J Hematol"},{"key":"2025121409572297000_13.3.e063605.6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24088"},{"key":"2025121409572297000_13.3.e063605.7","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3324\/haematol.2019.240846","article-title":"The variable manifestations of disease in pyruvate kinase deficiency and their management","volume":"105","author":"Al-Samkari","year":"2020","journal-title":"Haematologica"},{"key":"2025121409572297000_13.3.e063605.8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bjh.15758","article-title":"How we manage patients with pyruvate kinase deficiency","volume":"184","author":"Grace","year":"2019","journal-title":"Br J Haematol"},{"key":"2025121409572297000_13.3.e063605.9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/ejh.13128","article-title":"The burden of disease in pyruvate kinase deficiency: patients\u2019 perception of the impact on health-related quality of life","volume":"101","author":"Grace","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025121409572297000_13.3.e063605.10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/bloodadvances.2021004675","article-title":"Health-Related quality of life and fatigue in children and adults with pyruvate kinase deficiency","volume":"6","author":"Al-Samkari","year":"2022","journal-title":"Blood Adv"},{"key":"2025121409572297000_13.3.e063605.11","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2020.8305","article-title":"Successful allogeneic bone marrow transplantation using immunosuppressive conditioning regimen for a patient with red blood cell transfusiondependent pyruvate kinase deficiency anemia","volume":"12","author":"Shimomura","year":"2020","journal-title":"Hematol Rep"},{"key":"2025121409572297000_13.3.e063605.12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.177857"},{"key":"2025121409572297000_13.3.e063605.13","unstructured":"Rocket Pharmaceuticals, Inc . Rocket pharmaceuticals announces updated positive preliminary clinical data from phase 1 trial of RP-L301 for the treatment of pyruvate kinase deficiency. 2021. Available: https:\/\/ir.rocketpharma.com\/news-releases\/news-release-details\/rocket-pharmaceuticals-announces-updated-positive-preliminary [Accessed 7 Jan 2022]."},{"key":"2025121409572297000_13.3.e063605.14","unstructured":"Agios Pharmaceuticals, Inc . Pyrukynd (mitapivat) prescribing information. 2022. Available: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216196s000lbl.pdf [Accessed 19 Oct 2022]."},{"key":"2025121409572297000_13.3.e063605.15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa2116634","article-title":"Mitapivat versus placebo for pyruvate kinase deficiency","volume":"386","author":"Al-Samkari","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121409572297000_13.3.e063605.16","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(22)00214-9","article-title":"Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial","volume":"9","author":"Glenth\u00f8j","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025121409572297000_13.3.e063605.17","first-page":"185","article-title":"Establishing patient registries for rare diseases: rationale and challenges","volume":"34","author":"Boulanger","year":"2020","journal-title":"Pharmaceut Med"},{"key":"2025121409572297000_13.3.e063605.18","doi-asserted-by":"crossref","unstructured":"Gliklich RE , Leavy MB , Dreyer NA . Registries for evaluating patient outcomes: A user\u2019s guide. 4th ed. Rockville (MD): Agency for Healthcare Research and Quality (US), 2020.","DOI":"10.23970\/AHRQEPCREGISTRIES4"},{"key":"2025121409572297000_13.3.e063605.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i3319","article-title":"Patient focused registries can improve health, care, and science","volume":"354","author":"Nelson","year":"2016","journal-title":"BMJ"},{"issue":"Supplement_1","key":"2025121409572297000_13.3.e063605.20","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123059","article-title":"An ongoing global, longitudinal, observational study of patients with pyruvate kinase deficiency: the peak registry","volume":"134","author":"Grace","year":"2019","journal-title":"Blood"},{"key":"2025121409572297000_13.3.e063605.21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ejh.13572","article-title":"Comorbidities and complications in adults with pyruvate kinase deficiency","volume":"106","author":"Boscoe","year":"2021","journal-title":"Eur J Haematol"},{"key":"2025121409572297000_13.3.e063605.22","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29148","article-title":"Pyruvate kinase deficiency in children","volume":"68","author":"Chonat","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2025121409572297000_13.3.e063605.23","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1002\/ajh.25926","article-title":"Characterization of the severe phenotype of pyruvate kinase deficiency","volume":"95","author":"Al-Samkari","year":"2020","journal-title":"Am J Hematol"},{"key":"2025121409572297000_13.3.e063605.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0936-x","article-title":"From scientific discovery to treatments for rare diseases-the view from the National center for advancing translational sciences-office of rare diseases research","volume":"13","author":"Kaufmann","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2025121409572297000_13.3.e063605.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0836-0","article-title":"Rare disease registries: potential applications towards impact on development of new drug treatments","volume":"13","author":"Jansen-van der Weide","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2025121409572297000_13.3.e063605.26","unstructured":"Bianchi P , van Beers EJ , Vives Corrons JL , et al . Baseline characteristics by age of a global cohort of patients diagnosed with pyruvate kinase deficiency \u2013 a descriptive analysis from the peak registry [abstract]. EHA 2021:EP691."},{"key":"2025121409572297000_13.3.e063605.27","unstructured":"Peak registry. 2022. Available: https:\/\/peakregistry.com [Accessed 17 Nov 2021]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:57:30Z","timestamp":1765735050000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,23]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/bmjopen-2022-063605"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063605","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}